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Abstract: Understanding molecular mechanisms underlying the complexity of allosteric regulation
in proteins has attracted considerable attention in drug discovery due to the benefits and versatility
of allosteric modulators in providing desirable selectivity against protein targets while minimizing
toxicity and other side effects. The proliferation of novel computational approaches for predicting
ligand–protein interactions and binding using dynamic and network-centric perspectives has led
to new insights into allosteric mechanisms and facilitated computer-based discovery of allosteric
drugs. Although no absolute method of experimental and in silico allosteric drug/site discovery
exists, current methods are still being improved. As such, the critical analysis and integration of
established approaches into robust, reproducible, and customizable computational pipelines with
experimental feedback could make allosteric drug discovery more efficient and reliable. In this article,
we review computational approaches for allosteric drug discovery and discuss how these tools can be
utilized to develop consensus workflows for in silico identification of allosteric sites and modulators
with some applications to pathogen resistance and precision medicine. The emerging realization that
allosteric modulators can exploit distinct regulatory mechanisms and can provide access to targeted
modulation of protein activities could open opportunities for probing biological processes and in
silico design of drug combinations with improved therapeutic indices and a broad range of activities.
Keywords: Allostery; allosteric modulators; network analysis; MD-TASK; drug resistance; precision
medicine
1. Introduction
Allosteric regulation is often a mechanism of choice for proteins and biomolecular assemblies
to operate in complex signalling cascades and to modulate their activity levels, adapting to binding
partners in the cellular environment during signal transduction, catalysis, and gene regulation
[1–5]. The advances in X-ray crystallography, Nuclear Magnetic Resonance (NMR), and biophysical
techniques have enabled numerous detailed investigations of large protein systems and conformational
dynamic processes at atomic resolution [6–19]. These developments have facilitated the integration
of computational and experimental studies of allosteric regulation, eventually leading to new
conceptual outlooks and attempts to develop a unified theory of this allosteric phenomenon. The
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thermodynamics-based conformational selection model of allosteric regulation has been particularly
fruitful in explaining a wide range of experiments by assuming that a statistical ensemble of preexisting
conformational states and communication pathways is inherent to any protein system and can be
modulated through allosteric ligand perturbations [20–26]. While great leaps have been made in the
field of molecular modelling, NMR spectroscopy, and X-ray crystallography, it should be noted that no
single method can provide allostery information for all cases due to the complexity and incomplete
understanding of allosteric phenomena.
Understanding molecular mechanisms of allosteric regulation in proteins has attracted
considerable attention in both academia and industry owing to the importance of discovering allosteric
modulators of therapeutically important targets [27]. These efforts are motivated by fundamental
differences in structural and evolutionary diversity between active and allosteric sites even among
structurally similar proteins of the same family. While active sites for structurally related proteins and
protein families are often highly conserved and present a formidable challenge for design of selective
modulators, allosteric binding is typically more dynamic and structurally and evolutionarily diverse,
thereby often alleviating conceptual difficulties in the design of target-specific therapies and addressing
lingering problems of toxicity and side effects [28]. Another important incentive for the development
of allosteric drugs is that, while traditional orthosteric drugs usually inhibit protein activity, allosteric
modulators may not only inhibit but also increase protein activity (allosteric activators) [29]. In the last
decade, drug discovery has been shifting its focus toward targeting allosteric sites in order to improve
compound selectivity [28–33]. Allosteric drugs also feature distinct physicochemical properties, adding
further freedom for discovery of novel active compounds, and can often be combined with orthosteric
drugs into synergistic drug cocktails to modulate and improve enzyme activities, specificity, and
pharmacological profiles.
While orthostery-based therapies have enhanced the quality of life for patients, they have brought
forth many daunting challenges for which allostery may provide new solutions. Drug discovery against
more diverse protein targets can result in less toxic and more specific therapies. The incorporation of
dynamic and network analysis tools has proven their effectiveness in drug discovery studies of several
target proteins [32–35] and offer a promising direction for the analysis of large datasets [36]. With the
maturation of open-source projects, the availability of cheaper computation, and large datasets, in silico
simulations are a very attractive venture for early-stage drug discovery as they offer cost-effective
drug development. The integration of such approaches into robust, reproducible, and customizable
workflows should make in silico allosteric drug discovery more efficient and reliable. In this review
article, we discuss how the integration of state-of-the-art structural, dynamic, and network-based
approaches for simulation of ligand–protein binding can provide a comprehensive methodological
framework for advancing computer-aided discovery of allosteric sites and allosteric modulators of
protein functions and mechanisms.
2. Part I: Overview of Allostery and Allosteric Drugs
2.1. What is Allostery?
Allostery is generally defined as a reversible functional and conformational modulation at one site
resulting from a remote perturbation in a protein [27,37,38]. These remote events can be instantiated
from both covalent (residue mutations and chemical reactions) and non-covalent (intermolecular
interactions) events and are well-summarized by Nussinov and Tsai [27]. The phenomenon is also
extended to include entropic changes, which may prevail even when no conformational change may
be apparent [39–41]. Allostery-driven conformational changes are not expressed as two discrete
conformational transitions but rather exist as an equilibrium comprising a population of various
conformations [42]. More generally, allostery is an inherent property of biomacromolecules [43] and
its dysfunction is linked to the cause of several diseases [27]. Two examples of inherent allosteric
mechanisms include the protein binding by a hormone to drive conformational changes that affect
Int. J. Mol. Sci. 2020, 21, 847 3 of 41
protein–protein interactions in signalling cascades and small molecules regulating catalytic activity by
binding at loci far from an active site [44].
2.2. Understanding Allosteric Mechanisms Using Existing Approaches
Allosteric effects are not easily detectable by any single method as they can take many forms,
and a diverse pool of conformational samples is often needed to expose these rare events [41,45–47].
Current understanding of the details of allosteric mechanisms is still fragmentary [48]. However,
the recent experimental breakthroughs in NMR technologies have enabled structural studies of large
protein systems and conformational dynamic processes at atomic resolution, providing unique insights
into allosteric mechanisms [12,14,15,17,18]. While studies of allosteric regulation often emphasize
thermodynamic aspects of the mechanism and incorporate a population-shift conformational selection
paradigm, the critical role of conformational dynamics delineated in NMR studies led to the
development of the “dynamics-driven” framework of allosteric phenomenon. In dynamics-driven
allostery, effector ligands can induce allosteric effects through global redistribution of protein
fluctuations and can propagate signals through dynamic modulation of functional motions even
in the absence of visible structural changes [5,13,49–52]. Recent time-resolved infrared spectroscopy
experiments have indicated that allosteric transitions occur on multiple timescales. A time-dependent
view of allosteric communication revealed that allostery can be manifested by hierarchical propagation
of structural and dynamical changes, suggesting a high degree of conformational heterogeneity of
the ensemble of communication routes in proteins [53,54]. Relaxation dispersion NMR methods
have also enabled the detection of rapid conformational exchanges between ground and excited
states occurring on the µs–ms timescale that facilitated characterization of hidden excited states that
play a significant role in dynamic modulation of protein function and allosteric mechanisms [14,15].
Structural identification and characterization of lowly populated states by high-pressure NMR can
allow for detection of reversible transitions under thermodynamic equilibrium conditions that are
functionally relevant for allosteric mechanisms [55,56]. Pressure-dependent chemical shifts may
also measure redistributions in conformational entropy and specify dynamic allosteric mechanisms,
offering an exciting experimental platform for design of allosteric modulators specifically targeting
lowly populated functional states [55–57].
Allosteric interactions and communications can be conveniently described and characterized by
dynamic networks of interactions between components of biological systems. The organization and
evolution of dynamic residue interaction networks in proteins allows for formation of ensembles of
pathways that transmit signals by propagating conformational fluctuations and functional motions
between distant sites. Recent years have witnessed the development of various approaches that
investigate NMR chemical-shift perturbations to identify allosteric networks in proteins [58–63].
The ensembles of allosteric communications and protein residues involved in signal transmission
via population-shift or dynamics-based allostery can be experimentally examined by NMR
spectroscopy [64–66]. NMR chemical shift responses to bound ligands are commonly employed
as diagnostic tools for identifying coupled networks within allosteric proteins that could quantify
potential communication pathways [14,50,67].
NMR chemical exchange saturation transfer (CEST) experiments [68–70] can identify invisible
hidden states and characterize slow-to-intermediate conformational exchanges. NMR chemical-shift
covariance (CHESCA) and projection (CHESPA) analyzes can identify residue interaction networks
that show correlated changes in chemical shifts due to allosteric perturbations caused by ligand
binding or mutations [71–73]. NMR chemical-shift perturbations have also been combined with
Markov modelling and network analysis to reveal the dynamic flow of communication between
allosteric communities in proteins [74].
There is increasing evidence that dynamic allostery may be a common feature in many protein
interactions, and as a result, allosteric mechanisms are no longer viewed as being mediated solely
through structural transitions that select specific stable conformational states.
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Even though NMR technologies opened the doors to us to greatly understand the mechanisms
of allostery, over 80% of the structures available from the Protein Data Bank (PDB) comprise
macromolecules solved by X-ray crystallography [75]. These are a representation of the most frequent
conformations adopted by proteins from their respective pools of conformation ensembles [76]. As
allosteric sites are rarely observed in crystallographic structures, a large amount of conformational
sampling may be needed to uncover such high-energy states. For instance, cryptic (or hidden) allosteric
sites sporadically appear during conformational transitions of a protein in the presence of a bound
ligand. They are a recently discovered form of allostery whereby ligands can bind to pockets that are
not present in crystal structures [77]. These “hidden” allosteric sites are essentially invisible in crystal
structures, apart from some chanceful detection due to the stabilization of the rarer, higher-energy
conformation by certain compounds [78]. Fortunately, an abundance of computational tools have been
designed over the years to examine allosteric mechanisms in protein systems [36]. In silico conformation
sampling techniques allow us to unveil such rarely observed protein conformations [78] by simulating
protein motion, thus facilitating the discovery of potentially druggable sites [79]. Exhaustive sampling
is impossible, and highly precise quantum mechanics (QM) simulations are limited to small systems or
portions of larger systems. Coarse-grained molecular dynamics (MD), markov state models (MSMs),
and elastic network models (ENM) offer speed improvements by reducing complexity of all-atom
protein representation while maintaining topological and network integrity of protein systems that
drive allosteric mechanisms and global regulatory functions. The explored approaches have included
normal mode analysis (NMA) [80–83], MD [84], and machine learning [85]. Brown and coworkers
successfully coupled full-atom MD simulations to dynamic residue network (DRN) analysis to study
allosteric effects in disease-causing variants [86]. These computational approaches will be further
discussed in the second part of this review article.
2.3. Understanding the Allosteric Effects of Disease and Drug-Resistant/Sensitive Mutations—Precision
Medicine
Human diseases and traits have been associated with single nucleotide polymorphisms (SNPs)
through the use of genome-wide association studies (GWAS) [87,88]. There is even considerable genetic
variation between just two random individuals, where 10,000 non-synonymous single nucleotide
polymorphisms (nsSNPs) were found to exist between their exomes [89]. These mutations have
the potential to alter distal functional sites of enzymes by means of allosteric signalling—where
the dynamics of the entire structure is transformed as a result of the mutation [90–92]. Fortunately,
progress in allosteric research has made it possible to determine allosteric molecular mechanisms in a
myriad of allosteric systems in much detail [93]. For example, network analysis is usually performed
to determine the pathways that connect the mutation and the active site and aids in the study of
allosteric communication [86,94,95]. A recent publication studied six validated non-synonymous single
nucleotide variations (nsSNVs) to identify underlying mechanisms responsible for CA-II deficiencies
resulting in the phenotype of osteopetrosis with renal tubular acidosis and cerebral calcification [96].
In this study, Sanyanga et al. combined MD and DRN [97] analysis and showed that nsSNVs have
indirect/allosteric effects, providing greater insights into SNV mechanism of action. Hence, the study
proposed taking steps towards the treatment of CA-II deficiencies. Further, the authors highlighted the
importance of studying missense mutation effects in proteins with combined approaches and, hence,
in a broader sense, precision medicine-related research. This computational approach is detailed in
Subsection 3.3.5.
Precision medicine combines pharmacology and genomics to exploit genetic variation in the
human population in order to deliver innocuous but powerful drugs to certain groups of individuals.
This is based on the idea that an individual’s genetic makeup determines their reaction to a drug,
good or bad [88,98]. For instance, mutations can be linked to altered drug sensitivities in patients
[99–101]. This opens the door to personalized medicine, where knowledge of drug-resistant and
drug-sensitive SNPs can assist in the development of effective biomarkers [99] and allow treatments to
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be tailored to individual patients [102,103]. Furthermore, understanding structural changes caused
by nsSNPs would enable the design of novel drugs to target these mutations and, thus, is key in
advancing precision/personalized medicine [104,105]. One example can be given from stroke and
stroke-related medications. Clopidogrel and Warfarin, antiplatelet/anticoagulant drugs, are widely
used for primary and secondary prevention of stroke. It has been shown that genetic polymorphisms
resulting in reduced function of cytochrome P450 2C19 (CYP2C19) were associated with increased
cardiovascular risk and mortality in coronary artery disease patients on clopidogrel treatment. A study
of clopidogrel response in the Amish population indicated that the CYP2C19*2 variant accounts for
12% of the variation in platelet aggregation after clopidogrel treatment for 7 days [106]. A recent review
identified that, among patients with ischemic stroke and being treated with clopidogrel, carriers of
CYP2C19 loss-of-function alleles (*2, *3, and *8) have increased risk of recurrent stroke and composite
vascular events compared to noncarriers [107]. Another example can be taken from efavirenz, an
antiretroviral medicine, metabolized by cytochrome P450 2B6 (CYP2B6), UDP-glucuronosyltransferase
2B7 (UGT2B7), and CYP2A6 [108]. In this study, the authors investigated SNP associations with plasma
drug levels in Zimbabwean HIV-positive patients and observed elevated plasma levels of efavirenz,
which may lead to toxicity in patients due to CYP2B6*6 and CYP2B6*18 mutations. In both cases, the
molecular mechanism is not known. The integrated protocol suggested in Part II would be a good
starting point to elucidate the mechanism of the variations in drug sensitivity and to understand the
allosteric effects of the mutations.
Mutations have also been associated with drug resistance in numerous pathogenic diseases such
as influenza [109], tuberculosis [110], malaria [111], and HIV/AIDS [112]. A detailed understanding of
pathogenicity as well as drug-resistance mechanism(s) would be essential for designing novel therapies.
Sequencing the genome of pathogens can identify the drug-resistant and drug-sensitive mutations and
leads to a deeper understanding of the cognate molecular mechanisms. One example can be given
from a recent article by Sheik Amamuddy and colleagues [113]. The authors looked at eight Food and
Drug Administration (FDA)-approved drugs and the mutations of HIV protease due to drug usage.
As shown in Figure 1, the investigated mutations were interspersed within the protein (observed from
collections of variants) and were not limited to the orthosteric site. While not explicitly designed to
extract out the effects of specific allosteric mutations in the study, the method was able to expose
underlying conserved signals buried within noisy dynamic data generated from the combined effect
of orthosteric and allosteric mutations. The signals comprised a conserved and practically symmetrical
lateral expansion coupled to an inward contraction captured from an ensemble of simulations. This
method can easily be adapted to investigate allosteric events by designing an experiment-comprising
allosteric loci, which in the case of HIV protease, for instance, could be accessory DRMs (resistance
mutations not in contact with the antiretroviral drug) distal to the active site. Their approach combining
MD, network analysis, and statistical calculations indicated that, regardless of the drug used, these
mutations induce a common allosteric behavior in the protein in the presence of the drug, probably
to dislodge the latter from the binding site. Hence, understanding the allosteric behavior of the drug
targets due to mutations and identifying allosteric sites as alternative drug targeting sites would help
in the design of alternative modulatory molecules. Allosteric modulators, as explained in the following
section, would have many benefits over orthosteric drugs.
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Figure 1. Three-dimensional mapping of variation positions for the 8 FDA-approved HIV protease
inhibitors (atazanavir (ATV), darunavir (DRV), fosamprenavir (FPV), indinavir (IDV), lopinavir (LPV),
nelfinavir (NFV), saquinavir (SQV), and tipranavir (TPV)) used to investigate the effects of drug
resistance: Coloured cartoon representations depict the fulcrum, elbow, flap, cantilever, and interface,
while the variation loci are shown as red spheres. Even though single positions are shown, some
positions comprise multiple residue variations, some of which are validated drug resistance mutations
(DRMs) (as per the 2017 update [114]). Figure obtained from Reference [115].
2.4. Orthosteric versus Allosteric Drugs
Orthosteric and allosteric drugs are distinguished from each other by their molecular mechanism
of action. The former generally binds to the active site and is in competition with biological cofactors
or substrates. Alternatively, allosteric drugs and modulators can modify or obstruct the active site
when bound to an allosteric site. As allosteric binding sites are significantly less conserved compared
to orthosteric sites, the principal advantage of allosteric drugs lie in their higher specificities and
thus lower risks of toxic side effects [116–119]. In contrast, orthosteric site conservation allows an
orthosteric drug to bind not only to the intended protein but also to unintended homologous protein
family members, contributing to adverse side effects. Off-target toxicities are widespread amongst
anticancer drugs in clinical trials [120]. Allosteric sites are also highly enriched in hydrophobic residues,
whereas orthosteric sites are enriched with polar residues [43]. A study by Smith and colleagues hinted
at the higher rigidity and aromaticity of allosteric modulators [121], thus providing an additional
criterion for selecting modulators that are more likely to bind to an allosteric site. Allosteric modulators
induce conformational changes and distal effects on the orthosteric site residues [122]. Understanding
the structural and molecular mechanism of the induced effects is important for the rational design of
allosteric modulators and site identification.
Orthosteric drugs have been successfully used in therapy, for instance, to reduce viral loads in
HIV patients to undetectable levels [123]. Unfortunately, the selective pressures of drug treatment
have brought forth associated transmissible drug resistance mutations (DRMs), which render these
same drugs less effective over time, thus constraining future treatment strategies [124]. Some critically
important examples of drug resistance concerns include the emergence of extensively drug resistant
tuberculosis [125], where typical treatment options cease to work, and the recent surge of multidrug
drug-resistant HIV across Africa, America, and Asia [126]. The last report issued by the Centers for
Disease Control and Prevention listed 18 antibiotic resistant pathogens, including those resistant to
many commonly prescribed antibiotics [127]. The discovery and use of novel allosteric drugs may
therefore open the door for a wider array of future therapies as their more diverse loci could alleviate
selection pressures from the currently low-performing orthosteric drugs.
Targeting allosteric sites of functional proteins in Mycobacterium tuberculosis (Mtb) has played a key
role in research towards alleviation of TB. The protein pyruvate kinase was observed to exhibit some
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allosteric mechanism and deemed an attractive target of Mtb therapy [128]. Similarly, an allosteric
inhibitor was identified for the Mtb enzyme ornithine acetyltransferase [129] and yet another for the
enzyme tryptophan synthase [130]. Bacterial and viral infection agents can be targeted by looking at
proteins common to them. Rab II is a protein from the Rab family of GTPases and has been identified
as important in a number of disease-causing agents, including influenza A virus; pneumonia, caused
by Chlamydia pneumoniae; and Chlamydia trachomatis, which causes a number of sexually transmitted
infections by associating with other proteins to facilitate transport processes in the cell [131–133]. This
protein has been shown by Kumar et al. to possess allosteric-binding sites, and its allosteric inhibition
would be an effective remedy option towards eradication [134]. Another good example showcasing
the relevance of allosteric research in disease alleviation is the case of the American trypanosomiasis
(Chagas disease), where pockets with allosteric potential were identified and characterized in a cysteine
protease (cruzain) in efforts to inhibit the causative agent Trypanosoma cruzi [135].
2.5. FDA-Approved Allosteric Drugs
Protein allostery research has been ongoing for years, and our understanding of protein allosteric
modulation is strengthening [43]. Publicly available data concerning protein allosteric sites and
their modulators is steadily increasing—the AlloSteric Database (ASD) now holds over 1900 protein
targets and more than 82,000 allosteric modulators [136]. Despite continually growing investment
in allosteric research, only 19 of these modulators are approved drugs compared to the current
total of more than 3700 approved drugs [136,137], almost all of which bind to an orthosteric site
[138]. This comparison exposes the difficulty of allosteric drug discovery. The paucity of allosteric
modulators most likely results from a mixture of their reduced binding affinity, their relatively higher
hydrophobicity compared to orthosteric ligands [139], and their frequently adverse structure–activity
relationships [30]. Furthermore, the discovery of initial hit compounds is impeded by the difficulty in
detecting allosteric binding sites as well as the shortage of knowledge of allosteric interactions and
their consequences for protein modulation [43]. To date, only one approved allosteric drug has been
discovered solely using in silico methods, namely enasidenib (Table 1). Overall, there is a substantial
need for the elucidation of protein–modulator interactions in allosteric binding.
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Table 1. List of currently approved allosteric drugs [136] in alphabetical order.
Drug/code
name
Medical condition Mechanism Enzyme target Discovery Method 2D structure
Carglumic
Acid
Acute hyper-
ammonaemia
Activator Carbamoyl
phosphate
synthetase 1
Experiments in rats, both in vivo
and in vitro [140]
Cinacalcet Hyper-
parathyroidism
Activator G protein-
coupled
receptor
Functional responses of cells
regulated by calcium receptor
activity: PTH secretion by
parathyroid cells, calcitonin
secretion by C-cells, and bone
resorption by osteoclasts. [141]
Clonazepam Epilepsy Activator γ-amino-
butyric acid
(GABA)
Perifused frog neuro-
intermediate lobes [142]
Cobimetinib Melanoma Inhibitor MAPK1, MEK1
& MEK2
Structural insight - manipulation
of previously known MEK
inhibitors’ structure. Ligand-
binding affinity assays [143]
Cyclothiazide Hypertension Activator AMPA Receptor AMPA- and KA-induced
[3H]NE release from slices of rat
hippocampus [144]
Int.J.M
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Drotaverine Irritable bowel
syndrome
Inhibitor L-type Ca2+
channel
Saturation studies. Dissociation
kinetics [145]
Enasidenib Acute myeloid
leukemia
Inhibitor IDH2 In silico: Binding free energy,
conformational change [146]
Flurazepam Insomnia Activator GABA-A
receptor
Site-directed mutagenesis.
Concentration-response analysis
[147]
Ivermectin Parasite
infestations
Activator Alpha7
neuronal
nicotinic
acetylcholine
receptor
Mutagenesis. Cell line, culture,
and recordings [148]
Ketazolam Anxiety disorder Activator GABA-A
receptor
Increase of GABA level in cat
spinal cord and in the total brain
of mice and rats [149]
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Lorazepam Anxiety disorder Activator α1-adrenergic
receptor
Transfection. Ligand-binding
affinity assays [150]
Maraviroc HIV Inhibitor C-C chemokine
receptor type 5
Displacement binding assays.
Dissociation kinetics [151]
Niclosamide Neuropathic pain Inhibitor Group 1
metabotropic
glutamate
receptor
Calcium mobilization assays.
Cross-receptor selectivity
experiments. Computati-
onal molecular modeling
analysis. NP-evoked mechanical
hyperalgesia model in rats [152]
Piracetam Dementia, vertigo,
cortical myoclonus,
dyslexia, and sickle
cell anemia
Activator AMPA Receptor Enzyme crystallization. Crystal
structure determination.
Structure analysis [153]
Int.J.M
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Rifapentine Tuberculosis Inhibitor DNA-
dependent RNA
polymerase
Site-directed mutagenesis. In
vitro transcription. RFP binding
assays [154]
Rilpivirine HIV Inhibitor HIV-1 reverse
transcriptase
X-ray crystallo- graphy.
Molecular modeling.
Optimizing lead compounds
[155]
Sirolimus Immuno-
suppressive
Inhibitor FK Binding
Protein-12
Site-directed mutagenesis.
FKBP12- Rapamycin (Sirolimus)
binding assays [156]
Ticagrelor Stroke; Acute
coronary syndrome
undergoing
percutaneous
coronary
intervention
Inhibitor G protein-
coupled
receptor
ATP analogue production.
Platelet inhibition and patient
outcome (PLATO) trial [157]
Trametinib Melanoma Inhibitor MEK1 & MEK2 Enzymatic and cellular studies.
Pharmacokinetic analysis [158]
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3. Part II: An Integrated In Silico Approach for Allosteric Drug Discovery
3.1. The Main Workflow
Central to this work, we propose an integration of in silico approaches that can be used for
allosteric drug discovery (Figures 2 and 3). The proposed workflow has been developed as a result of
our research over the last few years, as indicated below and in the sections that follow. The workflow
diagram gives a complete picture of all techniques, but in a particular case, only some of the approaches
would actually be used. Our holistic approach starts with the acquisition of a high-quality drug target
and goes through a series of approaches for allosteric site prediction before finally proceeding to the
identification of allosteric modulators. We emphasize that the structural reliability of the chosen target
is of utmost importance for the success of the subsequent steps. As done for most in silico allostery
detection approaches, we start by finding putative allosteric binding sites before zooming onto them
to determine and characterize possible binders by analyzing stabilities from conformational sampling
processes. As many of the approaches and methods are common between allosteric site and allosteric
modulator identification, we will follow the order given in Figure 2A while introducing them. Some of
the approaches were shown to be in agreement with each other (Figure 2B). These will be indicated
where necessary.
Figure 2. (A) Our proposed integrated workflow for allosteric site identification, which starts with the
acquisition of a drug target and (B) different concepts and techniques from molecular simulation that
can provide correlating information to discover and characterize allosteric events in proteins.
Some examples of the use of the proposed workflow to investigate allosteric phenomena
in proteins of medical significance are as follows: (1) Perturbation response scanning (PRS) was
combined with all-atom MD and DRN to investigate the allosteric potential of remote residues to
effect conformational changes [35] and has been supplemented with docking to investigate the distal
effects of ligand binding [29] in human Hsp protein; (2) homology modelling, docking, MD, essential
dynamics, and DRN were jointly used to identify allosteric modulators of malarial Hsp, after which
coarse-grained conformational sampling simulations coupled to residue network analysis showed
corroborating results, obtained from a fraction of the computation time required compared to the
all-atom simulations [33]; and (3) allosteric effects associated to alpha carbonic anhydrase SNVs were
discovered by coupling all-atom MD to DRN—further characterization was achieved using essential
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dynamics and binding free energy landscape analysis [96]. As can be observed from these examples,
one has a better chance of discovering and characterizing allosteric events by combining multiple
techniques, among which simulating protein motion and coupling to DRN appear to be very effective.
Figure 3. Our proposed integrated workflow for identifying allosteric modulators.
3.2. Allosteric Site and Modulator Prediction
3.3. Drug Target Acquisition
As a first step for in silico allosteric modulator identification, one requires a target protein.
Three-dimensional structures for the investigated target may already be available fully or in part
from the PDB [159]. In the absence of an experimental structure, a computational modelling approach,
such as homology modelling, can be used to model an entire protein. Further homology modelling may
be useful to insert non-synonymous residue variations using experimental structures as templates, but
it can also be used to impute missing ones from incomplete experimentally determined structures [86].
Over the years, the Research Unit in Bioinformatics group developed detailed homology modelling
approaches, and the methodology is given in a number of group articles [32,33,35,160–162].
There is a long list of user-friendly web servers available for modelling protein 3D structures,
some examples of which include I-TASSER [163], ModWeb [164], Phyre2 [165], PRIMO [166], RaptorX
[167], Robetta [168], HHPred [169], and SWISS-MODEL [170]. MODELLER [171] can be used as a
stand-alone tool by the more technically inclined users or when more customised solutions are needed,
such as loop refinement or when large volumes of modelling jobs are to be calculated. As a last
resort for target domains with no detectable homologs, ab initio modelling may be an option [172,173].
However, compared to the aforementioned target acquisition approaches (threading and homology
modelling), the latter is accurate only for small proteins [174,175]. More recently, a command-line
protein structure prediction tool based on a recurrent neural network has been developed, showing
promising accuracies and producing models in a fraction of the time using only a position-specific
scoring matrix and the target sequence as inputs [176]. Finally, before the structure can be used in the
subsequent steps, one should validate the quality of the models via local and global metrics. ANOLEA
[177], QMEAN [178], ProSA [179], Verify3D [180], and ModFOLD [181] are a few examples used to
determine local quality scores, while z-DOPE [182], resolution, and QMEAN are a few examples of
global metrics. Using the MODELLER tool, a per-residue profile of the z-DOPE can also be obtained
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for pinpointing poorly modelled regions [183]. As no single evaluation criterion is perfect, one should
investigate multiple metrics to ascertain the validity of the model. As a general rule in homology
modelling, (1) the template resolution should be as high as possible, while the R-free and R-value
should be minimal, as they are the residuals between experimental diffraction data and the predicted
crystallographic model, and (2) the environmental conditions should closely match those that are to be
experimented on [184], such as the presence of a co-crystallized ligand and the receptor protonation
states. Unfortunately the presence of certain molecular entities may require some prior planning due
to the incomplete transferability across certain force fields [185] for use in downstream approaches
(such as MD). Finally, given that differences in receptor conformation specify different topologies and
alter the ligand-accessible surfaces, it is clear that this plays a major role in experimental designs aimed
at discovering allosteric sites.
3.3.1. Mining Literature and Databases for Allostery Information
Before attempting to identify an allosteric site of a protein, it is good practice to determine whether
the literature already describes it from previous work. The AlloSteric Database (ASD), which hosts
a collection of known allosteric targets and their modulators, is a major source of relevant literature
and annotations pertaining to the concept of allostery [136]. The database has grown to become a
central resource for the storage, retrieval, and analysis of allosteric protein datasets [136,186,187]. It
organizes information about allosteric regulation by receptor target and modulator (activator, inhibitor,
or regulator), and entries incorporate additional annotations such as the associated interactions, sites,
pathways, functions, and any linked disorders [136]. A good example of the use of the ASD in allostery
research can be drawn from work done by Astl and Verkhivker [188]. Using information retrieved
from the database, they combined coarse-grained MD and residue interaction network to demonstrate
the differential effects of allosteric inhibitors and activators on the global dynamics and network
organizations within protein systems, comprising 300 diverse proteins and complexes. In the case of
insufficient information characterizing allostery within the chosen target protein, one can proceed to
cavity-finding approaches for the discovery and characterization of de novo allosteric sites.
3.3.2. Cavity-Finding Approaches
Pockets/cavities present in proteins might be functionally important and have been recognized
as conventional sites for ligand binding [189]. For those targets that are not well characterized for such
pockets, the identification of these sites is thus a starting point for potential allosteric-site prediction
and structure-based drug design, with the effects of ligand binding confirming allostery [190]. There
is a wide array of freely available cavity-finding tools, mostly in the form of web servers which use
a variety of approaches to provide potential starting points for the discovery allosteric sites. The
methods employed include, amongst others, the use of NMA, energy evaluations, machine learning,
and MD simulations. As features characteristic to allostery are not completely understood, no single
predictive method can be exhaustive and it is best to utilize a combination of approaches to increase
the level of support for the potential sites. Some of the most recent cavity-finding approaches are
summarized in Table 2.
3.3.3. Blind Docking
Small-molecule docking to a target protein can give us an indication as to whether and how
strongly a ligand might bind to a certain surface, but limiting the search space to a primary binding site
(i.e., targeted docking) can be oblivious to allosteric pockets. In blind docking (BD), the whole protein
surface is scanned for putative binding sites and is especially useful when one has not been determined
a priori [191–193]. Several studies have used BD for allosteric site identification, for which we give
some examples in this section. Iorga and colleagues have used BD of three known allosteric modulators
to reveal putative binding sites from the acetylcholine-binding protein and in homology-modelled
human nicotinic receptors [194]. Grant and coworkers identified potential allosteric pockets on the
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Ras protein catalytic domain via BD of 267 putative ligands from PubChem BioAssay database [195].
Pavlovicz and colleagues used BD to identify negative allosteric sites on the numan α4β2 and α3β4
neuronal nicotinic acetylcholine receptors [196]. Jin and colleagues used BD with tyrosine phosphatase
1B to reveal a hydrophobic and less conserved allosteric site in contrast to its negatively charged
but highly conserved active site [197]. Based on this study, an alternative drug-design strategy was
proposed. Lastly, a study by Chen and colleagues employed BD to explore a specific allosteric site for
non-peptidic inhibitors located behind the catalytic triad of the dengue virus-2 NS2B-NS3 protease
[198].
Due to the increased search space, stochastic strategies are typically used to make the exploration of
the larger target surface computationally tractable [199]. One way to overcome this limitation is to
divide the search surface [200] and/or to increase the search exhaustiveness.
In their pioneering paper introducing BD using AutoDock, Hetényi and van der Spoel
recommended over 100 independent docking runs with flexible ligands [192], which would
be analogous to the exhaustiveness parameter in AutoDock Vina, for example. Further, in a
comprehensive study evaluating ten common docking programs [201–210], Wang and colleagues
showed that these tools correctly predicted the ligand poses even though the binding energies could
not be estimated accurately [211]. As BD involves a larger volume to scan, the docking process can be
limited by efficiencies of the sampling algorithms and complexity of the scoring functions [193]. A
more accurate estimation of the ligand-binding energy was achieved via quantum mechanical (QM)
and semi-empirical QM-based rescoring schemes [212,213]. This rescoring scheme was successfully
applied to HIV-1 protease (with 22 ligands) [214], cyclin-dependent kinase 2 (with 31 ligands) [215],
and casein kinase 2 (with 23 halogenated ligands) [216].
Key regions important for the stability of subtilisin (an industrially important serine protease)
were determined using PRS, in which the covariance matrix was obtained from equilibrated portions
of MD trajectories [217]. PRS was, for the first time, applied to large, flexible proteins by Penkler et
al. (2017), determining key residues involved in allosteric control in the 70 kDa heat shock protein
(Hsp70) [218] using an implementation of the PRS algorithm available from the MD-TASK package [97].
More recently, the same approach was coupled with DRN to determine potential effector residue loci
promoting allosterically driven conformation interconversions in human Hsp90 [35] before targeting
the same sites (at the C-terminus) by high-throughput virtual screening for druggable pockets [29].
After Penkler’s work showcased the application of PRS to highly dynamic proteins, Amusengeri and
Tastan Bishop employed a similar workflow in their work in Hsp72 and Hsc70 to search for allosteric
modulators [32] from the South African natural compounds database (SANCDB) [219]. While linearly
impacting a protein allows us to promptly assess the likelihood of transitioning from a static starting
state to a target state, measuring and summarising topological changes from conformational sampling
processes opens up a new avenue for the detection and characterization of allosteric effects, which
we describe in the next section focussed on the application network analysis in assessing protein
dynamics.
Int.J.M
ol.Sci.2020,21,847
16
of41
Table 2. Web servers for the prediction of allosteric sites.
Web server and
URL
Functionality Input Output
AlloDriver [220] Identifies potential driver mutations
implicated in cancer and maps them
to binding sites.
A list of annotated
cancer-related mutations.
Returns a list of ranked driver mutations annotated
by residue loci, scores and binding site (allosteric and
orthosteric), amongst many other features.
AlloFinder [221] AlloFinder identifies possible allosteric
sites via dynamic perturbations and
algorithms present in Allosite. It also
screens for possible binders against
the identified sites. Protein-ligand
complexes are then scored using
Alloscore algorithms.
The receptor PDB file and
a ligand library.
Displays protein-ligand complex for docked ligands within
the putative allosteric site. Further, a table reports the
volume of the predicted allosteric site, the perturbation score,
the drug-like score, the allosteric site score and the AlloScore
score. Additionally, the top 100 potential allosteric ligands
are ranked according to their Alloscore. Finally, the predicted
site and the predicted ligands are mapped using allosterome
data.
AlloPred [82] Uses NMA to identify potential
allosteric pockets.
The receptor PDB file and
active site residues.
Displays protein structure and a list of pockets with Allopred
and Fpocket rankings as well as NMA effect per residue.
Alloscore [222] Uses a linear combination of
non-bonded interaction terms, a
deformation term and geometric
features to predict the binding affinities
of protein-ligand interactions.
The receptor PDB file
and a pre-docked ligand
MOL2 file.
File with potential ligands and their allosteric interactions
(hydrogen bonds, van der Waals, hydrophobic interactions
and Alloscore values).
AlloSigMA [223] Calculates energetics of allosteric
signalling resulting from ligand
binding, mutations or a combination of
the two.
The receptor PDB file. The allosteric free energy profile, colouring residues
according to difference in free energy between the ligand
bound and the apo-protein.
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Allosite 2.0 [85] Predicts allosteric sites by means of
pocket-based analysis and support
vector machine (SVM) classifier
algorithms.
The receptor PDB file. Window showing the structure and identified potential
allosteric sites. Pockets can be viewed on the displayed
protein structure. Properties of the pocket include: i) Its
volume, ii) Total solvent-accessible surface area (SASA), iii)
Polar SASA and iv) Druggability score
AllosMod [84] Makes use of MD simulations and
energy landscapes to identify allosteric
conformational changes.
The receptor PDB file and
its sequence.
Returns a zipped file of further input files to be MD-run by
the user via MODELLER and analysed using a provided
Python script.
Cavity
(Submodule
of CavityPlus)
[190]
Identifies cavities and provides their
respective drug scores.
The receptor PDB file. Displays the structure, potential cavities and constituting
residues with their respective drug scores, which determine
cavity druggability.
CorrSite
(Submodule
of CavityPlus)
[190]
Identifies possible allosteric sites from
those picked up by CavityPlus on the
basis of correlated motion between
allosteric and orthosteric cavities.
PDB file of a proposed
orthosteric site or
predetermined cavities
obtained from the Cavity
tool.
Displays the structure with mapped orthosteric and
allosteric sites. Cavities are labelled with their corresponding
correlation scores to the orthosteric site.
CovCys
(Submodule
of CavityPlus)
[190]
Identifies druggable cysteine residues
for covalent allosteric ligand design.
Cavities identified by the
Cavity web server.
Maps any of the selected sites onto the protein structure
and displays a table of Cys residues labelled by cavity ID,
targetability, pKa value, exposure and their pocket binding
affinity.
DynOmics ENM
[83]
Predicts allosteric communication
using ENM.
The receptor PDB file. i) JSmol window showing structure color-coded by the size
of motions driven by the slowest two modes, lowest mobility
(blue) to highest mobility (red) regions, ii) Molecular motions
animation, iii) Mapped RMSF, iv) 3D and 2D display
of selected modes, v) Cross correlations between residue
fluctuations, and vi) Inter-residue contact maps
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MCPath [224] Identifies regions in a protein structure
which may function in allosteric
communication using a Monte
Carlo-based approach.
The receptor PDB file
and pathway data (initial
residue index, length and
number of paths).
List of all pathways ranked according to their probabilities
and populated pathways. 3D structure onto which the top
three populated pathways and their residues are mapped.
PARS [81] Uses NMA to identify possible
allosteric pockets which, upon binding
of a ligand, cause a regulatory effect in
the protein.
The receptor PDB file and
its sequence.
Table with identified pockets ranked according to their
potential as allosteric sites.
SPACER [80] Combines ENM and docking to predict
allosteric communication.
The receptor PDB file. List of ligand binding sites, for which the following can be
explored: i) Local closeness - the output structure is colored
according to surface local closeness values, ii) Binding
leverage - quantifies the cost of the binding site deformation
in the presence of a ligand, and iii) Characteristics of the
communication strength between a putative allosteric site
and another binding site.
STRESS [225] Identifies allosteric hotspot residues
which result in large protein
conformational changes when bound
by a small ligand.
The receptor PDB file. Ranked list of predicted sites each with an index of the
binding site obtained from Monte Carlo simulations, a
binding leverage score and their respective residues.
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3.3.4. Perturbation Response Scanning
By factoring out the bound small molecule, to instead perturb single residues from a receptor and
to record the linear response, is a rapid way of approximating biological perturbations in proteins.
These perturbation events can be instantiated by various intrinsic and extrinsic factors, which may in
turn have far-reaching effects [27,36]. In perturbation response scanning (PRS), a series of uniformly
distributed forces are sequentially applied to each residue of an equilibrated protein conformation to
estimate the agreement with a desired target state [226]. The perturbation is obtained from the dot
product between a covariance matrix and a force vector. The covariance matrix can be obtained from
various models of interatomic potential such as those used in MD [29] or by inverting a Hessian matrix
[227] as typically done in ENM [226]. The uniform force vector impacts a given residue multiple times,
and a correlation consensus is obtained for that residue’s overall effect against a targeted conformation.
The algorithm is sequentially applied to each residue of the protein to yield a correlation value in each
case. The PRS algorithm has been successfully used to uncover mechanisms of allostery in various
experiments. For instance, Gerek and Ozkan used PRS to compare allosteric transitions in two PDZ
domain proteins (proteins linked to cancer and to Alzheimer’s and Parkinson’s diseases) by perturbing
inverted Hessian matrices obtained from ENM models [228].
3.3.5. Interaction Networks in Proteins Dynamics
The Usefulness of Network Theory in Investigating Protein Dynamics and Allostery
As reviewed recently by Liang and coworkers, the last decade has produced an array of
various tools that bridge multiple interdisciplinary concepts for the study of protein dynamics and
allostery regulatory mechanisms [36]. More specifically, in allosteric signalling, the perception and
long-distance relay of the trigger signal is associated with the rewiring of an intricately connected
network of non-covalently interacting protein residues [36]. This ultimately leads to directly observable
conformational changes and/or to entropic changes, where no conformational change is seen.
Simplifying the protein topology as a network of nodes connected by edges to represent the residues
and their interaction (or strength of interaction), respectively [23,229,230], allows for the investigation
at various levels of the allosteric effects, which are otherwise convoluted with protein entropy. The
increasingly popular integration of network theory for protein dynamic analysis thus plays a major role
in robustly deconvoluting complex relational behaviours into a more interpretable and quantifiable
form [230–240]. Several studies have pointed out the tremendous usefulness of modelling and
analyzing proteins as dynamic entities oscillating between various allosteric states in order to extract
meaning from the complexity of allosteric regulation [29,80,81,94,224,241–245].
Dynamic Residue Network Analysis
Networks are typically represented by either an adjacency matrix or an edge list [36]. In static
networks, a binary contact is inferred between each protein residue pair (defined by C-alpha or
C-beta atoms) using a defined cut-off distance (i.e., 6.7Å). The DRN approach extends this idea
by computing the time-averaged version of static contact networks using MD simulation data [97].
Different variations of time-averaged networks have been used to investigate allosteric effects in
various proteins, for instance, in characterizing (1) the dynamics of catalysis in Cyclophilin A variants
[95], (2) in characterizing the effects of damaging non-synonymous SNVs of the renin–angiotensinogen
complex [86] and carbonic anhydrase 2 [96], and (3) in investigating cross-domain allostery in human
heat shock proteins [29,32]. The MD-TASK package was the first downloadable tool packaging a set of
nonconventional methods meant to analyze MD simulations. These comprise a set of freely available
Python scripts aimed at computing DRN metrics in addition to other scripts used for carrying out MD
analysis [97]. More specifically, these network metrics comprise the time-averaged versions of both
betweenness centrality (BC) and averaged shortest path (L), calculated for each protein residue (node)
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using MD trajectory data. While BC measures the number of geodesics (shortest paths between two
nodes) going through an intervening node [246], L averages the number of geodesics inbound to a
node. Both metrics gain robustness in predicting medium-to-long-distance relational information from
averaged information across conformational ensembles. By computing the average geodesics between
every residue pair, L would effectively be maximized when a structure is compact and minimized
otherwise. As BC is evaluated for intervening residues linking pairs of residues, it gives a good
indication of the importance of that residue for information flow within the protein. Penkler et al. for
the first time showed that there is correlation between BC and 1/RMSF (root mean square fluctuation)
as well as between BC and 1/L [35]. Interestingly, the article also highlighted a high correlation
between PRS hot spot residues and residues with high BC values. This correlation, later, was also
identified in other studies [32]. More recently, Kimuda coupled DRN to the molecular mechanics
Poisson–Boltzmann surface area (MM-PBSA) analysis and principal components analysis (PCA) to
identify 18 novel potential inhibitors of pteridine reductase 1 in Trypanosoma brucei—the causative
agent of Human African Trypanosomiasis—five of which inhibited the pathogen’s growth in vitro
[247].
In a new approach developed by Sheik Amamuddy and coworkers, a statistically guided network was
able to show two coupled conformational changes associated with antiretroviral (ARV) drug resistance,
using one-tailed t-tests on collections of residue pairwise distances determined from ensembles of
protease structures sampled by MD [113]. Despite the presence of a multitude of nsSNVs and selected
DRMs, situated at multiple loci within the viral drug target, they were able to reproducibly detect
these motions in HIV proteases with a high degree of conservation across 8 FDA-approved inhibitors
despite the chaotic nature of protein dynamics. This technique, which combines t-tests and the degree
centrality, may hold a lot of promise for the analysis of alternate phenotypes (such as in the study
of drug resistance) and may be invaluable in the characterization of allosteric effects. The recently
published statistically guided network construction technique proved highly sensitive in detecting
distinct motions from ensembles comprising hundreds of drug-resistant and drug-sensitive HIV
protease variants, whereby present nsSNVs were dispersed within the protein structures [113]. The
calculation of the degree centrality in this approach is very attractive for making inferences from
batches of comparable protein variants, with potential applications in comparing allosteric effects
between alternate pairs of a given phenotype.
Coevolution and Residue Interaction Networks
A functional site that mediates communication pathways and determines organization of the
residue interaction networks often coincides or tightly couples with coevolving residues. Statistical
coupling analysis (SCA), mutual information (MI) model, and covariance-based approaches have
employed sequence-based analysis of residue coevolution in homologous families to show that
functional residues in residue networks are connected via strong evolutionary relationships [248–255]
Coevolution of protein residues can reflect correlated functional dynamics of these sites in mediating
residue–residue contacts [256], protein folding transitions [257], and allosteric signalling in protein
complexes [258]. Coevolving residues could also form direct communication paths in the interaction
networks with connections weighted according to dynamic couplings and coevolutionary interaction
strengths between nodes [259–261]. Structurally stable and quasi-independent modules of physically
interacting coevolving residues (protein sectors) appeared to play a key role in mediating protein
stability and long-range interactions [250,251]. Several computational methods have been developed
to evaluate the extent of mutual information and coevolutionary dependencies between residue
pairs [252,253,262–264]. Computational analysis of residue interaction networks and community
analysis have shown that local dynamic modules anchored around functional residues can serve
as building blocks to connect distant functional regions and to mediate allosteric conformational
transitions [94,252,265–268]. Dynamic and coevolutionary residue correlations may also act as
synchronizing forces that determine modular organization of allosteric interaction networks and
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enable efficient allosteric regulation [94,269,270]. These results have motivated the development of
novel community-based methods for modelling ensembles of allosteric communication pathways
in protein structures [94,269,270]. Using this computational framework, it was found that efficient
allosteric communications in various signalling proteins could be controlled by structurally stable
functional centers that exploit dynamically coupled residues in their local communities to propagate
cooperative structural changes.
After having scanned the structure of interest using the allosteric site prediction approaches to
obtain various sources of support for putative ligand binding sites, a consensus can be drawn before
proceeding to the identification of allosteric modulators.
3.3.6. Conformational Sampling
Molecular Dynamics
MD is an invaluable tool in the hands of protein allostery researchers [44]. MD experiments
simulate biological protein movement at various levels of theory, for which molecular mechanical
approximations (coupled to Newton’s second law of motion) [271] are the most common for
relatively large solvated protein systems. At the junction between the quantum and coarse-grained
atomic models, all-atom MD simulations provide a good trade-off between accuracy and speed for
conformational sampling, producing quality spatiotemporal data associated to protein action. To
investigate allostery, a researcher would typically dock a prospective binder against a protein of
interest before characterizing any ligand or protein changes. For such work, conventional methods
of analysis can be supplemented by DRN (Part II, section 3.3.5). These methods can also be used
to study the allosteric effects of protein variants. Utilizing sequence data, it is possible to elucidate
the mechanisms associated with disease-causing sequence variants using protein dynamics and
allosteric regulations [36,272]. All-atom MD may not be able to sample enough conformations under
reasonable computation time in the case of rare events or for changes that occur over longer periods.
Coarse-graining simulations and accelerated sampling approaches are the next best approaches and
are discussed in the next section.
Coarse-Grained Simulations and Stochastic Markov State Models
Coarse-grained models are computationally effective and enable simulations of long timescales
for large allosteric systems and assemblies, thereby allowing for observation of allosteric structural
and dynamic changes [33]. Functional and large-scale flexibility changes in allosteric systems can
be predicted using several popular coarse-grained methods such as CABS-flex [273–276], NMSim
[277], and FlexServ [278]. CABS-flex uses a coarse-grained model in combination with an efficient
search protocol [274,275] and allows the generation of trajectories that can accurately recapitulate the
all-atom MD simulations for long-time processes [274,275,279]. NMSim is a computationally efficient
alternative to all-atom MD simulations and can be employed for sampling of large conformational space
and pathway generation [277]. FlexServ method and server provides access to three coarse-grained
algorithms for simulations of protein flexibility: discrete dynamics, NMA, and Brownian Dynamics
[278]. These coarse-grained approaches provide robust and efficient means for simulation and analysis
of large conformational changes and allosteric transitions in protein systems that otherwise are
difficult to observe in all-atom MD simulations. ENM are a type of coarse-grained NMA, which can
substantially reduce the computational demands to efficiently explore protein dynamics around a single
energy minimum by simplifying interatomic interactions as spring-connected nodes (protein Cβ and/or
Cα atoms) [227,280,281,281–284]. Several studies involving this approach have verified its success in
identifying functionally relevant protein conformations [175,285–292]. Further, coarse-grained NMA
[293–295] and ENM integrated with the information-based Markovian theory of signal propagation
[296–303] have provided a generalized formalism of allosteric communication pathways in proteins.
Given the complexity of thermodynamic and kinetic factors underlying allosteric regulatory events,
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stochastic MSMs [304–310] have become increasingly useful states-and-rates network models with
the software infrastructure [311–314] for describing the probability of transitions between functional
states during allosteric events [77,315,316]. Combined with MD simulations, MSM approaches can
provide detailed network connectivity maps of states on the free-energy landscape and can estimate
the effect of allosteric perturbations on the conformational equilibrium and kinetics of allosteric
transitions. Rare transition events between long-lived states are a key feature of allosteric proteins that
are difficult to observe in direct MD simulations because of the long simulation timescales needed. To
circumvent these limitations, MSMs can be built from multiple shorter simulations yet describe long
timescale dynamics accurately. While protein structure network models describe allosteric interactions
between residue nodes, MSM network maps are markedly different by representing discrete protein
states as the system nodes. The connections between Markovian state modeling and network-centric
analysis of protein structure have never been rigorously explored for understanding of allosteric
processes, leaving a significant conceptual void in the current knowledge and the existing repertoire
of computational approaches. The integration of the experiment-informed Markovian modeling of
protein dynamics and the information-theoretical description of dynamic flows and entropy transfer in
the networks of protein states represents an interesting and promising avenue for further exploration
of allostery. Flow-based model methods [317–325] operate through a stochastic walk on the dynamics
of the network rather than on its topological structure, where communities consist of dynamically
interconverting conformations among which the dynamic flow can persist for a long time and define
functionally significant states. The apparatus of the map equation can reveal modular patterns in
the dynamic flows of allosteric proteins, allowing to map conformational transformations between
allosteric states and to reconstruct regulatory mechanisms.
In the following section, we describe some analysis strategies that have shown their efficacy in
investigation of allosteric effects using data obtained from conformational sampling.
3.3.7. Trajectory Analysis
After performing preliminary quality checks on the simulated protein dynamics data,
conventional metrics such as the root mean square deviation (RMSD), residue root mean square
fluctuation (RMSF), radius of gyration (Rg), and geometry calculations (distances and angles) can be
performed to infer the stabilities (or instabilities) within protein–ligand complexes for the previously
docked compounds [29,32,233,326,327]. Distal effects of interfacial residue variations within the
renin–angiotensinogen complex were uncovered by Brown and colleagues using RMSF alongside BC
[86]. Dynamic cross correlation (DCC) is an additional option for characterizing the residue motions
sampled from MD simulations, an example of which can be found from work done by Bowerman and
Wereszczynski to characterize the allosteric effects of a thrombin antagonist [328]. An implementation
of a DCC algorithm is available from MD-TASK. For a bird’s eye view of the distribution and clustering
of sampled conformations, essential dynamics (ED) can be supplemented with energies in free-energy
landscape (FEL) calculations to analyze the stability of protein complexes under various conditions
[329,330]. More specifically, it has been used by Amusengeri and Tastan Bishop to investigate the
effects of allosteric ligand binding in human heat shock proteins [32].
As each of the aforementioned methods highlights different facets of simulated protein dynamics,
we provide some details about their principles and the types of information that can be retrieved
using such techniques. In each case, the proteins or complexes are assumed to be free from periodic
boundaries and corrected from rotational and translational effects. In the following section, we describe
several approaches that can be used for analyzing results obtained from simulated protein dynamics.
RMSD
The root mean square deviation evaluated between a target and a given reference structure gives
an idea of the overall deviation of all atoms of the structure from those of the reference. The RMSD
evaluated at time ti is calculated as shown below, where N is the number of atoms, m is the atomic
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mass, x is the generalized coordinate, and tre f is the frame used as reference, being generally the frame
at t = 0:
RMSD(ti) =
√√√√ 1
N
N
∑
j=1
mj[xj(ti)− xj(tre f )]2 (1)
For an MD simulation, it is important that the structures are properly aligned such that correct
distances are evaluated. As it is often the case that trajectory-specific topologies are used in independent
simulations, care should be applied when interpreting and comparing pairs of such systems, for
instance, in an allosteric modulator-bound and a modulator-free protein or in a wild-type and a variant,
as each protein may have a slightly different starting conformation as reference. Work by Penkler and
Tastan Bishop comparing allosteric effects from ligand-bound and ligand-free Hsp90α clearly suggests
the presence of multiple receptor conformations, as seen from the multimodal distribution of RMSD
data [29].
RMSF
While RMSD calculates an average obtained from a collection of atom coordinates, an RMSF
value is computed for each atom as the standard deviation of atomic fluctuations recorded over time.
For each atom, the RMSF gives an estimate of its variability around its time-averaged value, once
more from aligned conformations. Comparing RMSF values for homologous residue positions across
two systems thus allows for the local inspection of differential residue flexibility, given an allosteric
perturbation.
RMSF(xi) =
√√√√ 1
T
T
∑
j=1
[xi(tj)− x¯i)]2 (2)
As an example of the use of RMSF for the detection and partial characterization of allosteric
effects, Brown and coworkers observed increased rigidities across several deleterious variants of
the renin-angiotensinogen complex with respect to the wild-type complex at sites distal to the dimer
interface where known nsSNVs had been introduced [86].
Radius of Gyration
In the calculation of Rg, radii are first computed between each atomic (rj) center of mass (COM)
and the molecular COM (Ri), before computing the RMSD to give an indication of the degree of
compactness for a protein at a given frame i.
Rg(ti) =
√√√√ 1
N
N
∑
j=1
mj[rj(ti)− R(ti)]2 (3)
A higher averaged radius hints at a less compact structure. For instance, a residue mutation
situated at the interface between two interacting protein surfaces may destabilize them and increase
the Rg value. Unless the protein conformational changes are large enough, one may not always find
significantly different Rg distributions. In such cases, one may focus on more localized regions, such
as an individual domain for example. Sheik Amamuddy and coworkers used Rg distributions as one
of their methods to investigate drug-resistance-related changes from ensembles of drug-resistant and
drug-susceptible HIV protease structures of the B subtype [113].
Dynamic Cross Correlation
In essence, DCC performs pairwise correlations of atomic motion, generally by normalizing
the covariance matrix over the product of the respective standard deviations of atomic fluctuations
recorded over time for each atom pair. Provided the simulations are not too short, this allows one to
compare motions that trend apart or together within a single system. As for the other metrics, it can be
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used to compare analogous systems that have experienced a given allosteric perturbation to determine
correlative properties from the experiment.
Geometry Calculations
Geometry calculations comprise the calculations of distances, bond angles, and dihedrals. For
example, one may compare the domain–domain distance in a multi-domain protein or the inter-residue
distances resulting from the introduction of a non-synonymous residue mutation or the binding of a
ligand at a site away from the active site. In an experiment investigating allostery-related effects in the
redox-dependent conformational dynamics in the multidomain human protein disulphide isomerase
(hDPI), Karamzadeh and coworkers computed several geometric features, such as the inter-domain
angles and distances, torsion angles, and pairwise residue distances in order to build machine-learning
classifiers able to discriminate between the redox states [331].
Essential Dynamics and Free-Energy Landscape
The application of ED to analyze protein behaviour mainly focuses on the dominant modes of
motion, which are obtained by decomposing the covariance matrix and by ranking the eigenvectors
(principal components) in descending order of the corresponding eigenvalues [292,332]. By plotting
the first two or three principal components against each other, we obtain a general idea of the
distribution for all generated conformations obtained from a conformational sampling experiment, as
exemplified from ED analyzes for various proteins [333–336]. On the resulting figure, one may obtain
conformationally distinct clusters of the simulated proteins or complexes. When supplemented with
energy levels, the 3D FEL plot effectively highlights areas of low and high energies, which typically
correspond to the metastable and transitory states respectively. According to the principle of minimal
frustration, troughs in the landscape are generally populated by the more native conformations [337].
Given an allosteric signal, the population of protein conformations can be shifted to an alternate state
against an otherwise higher energy barrier. The FEL is thus a very important tool in investigating the
allosteric effect, when conformational changes are present, as exemplified by a case study showcasing
the application of computational methods to discover allosteric modulators in malarial proteins [33],
and in the characterization of Discorhabdin N as potential allosteric modulators of anticancer drug
targets [32].
4. Conclusions
While we have gained important insights into the function of allosteric proteins, the quantitative
characterization of these highly dynamic and often elusive processes continues to present formidable
technical and conceptual challenges. Allosteric events in biological systems occur on different spatial
and temporal scales and involve a complex interplay of thermodynamic and dynamic changes that are
difficult to observe, simulate, and interpret.
Experimental studies of protein systems indicate that allosteric regulation may involve a combination
of the classical models of allostery, i.e., conformational selection, dynamic allostery, and induced fit. An
understanding, at the structural level, of the relationships between protein robustness, allosteric drug
binding, and disease may be of use in the development of theoretical and experimental approaches
bridging structure-based network analysis of protein targets with modelling of protein interaction
networks and pathways. The complexity and diversity of these processes require innovative theoretical
and data-driven approaches that can bridge advances in structural and quantitative biology in
transformative yet practical ways. The development of novel integrated research strategies should
address these challenges by strengthening and advancing the interface between molecular biophysics,
network biology, and data science. We argue that the next breakthrough in the discovery of allosteric
drugs may require such integration of traditional biophysical approaches with systems biology and
experiment-guided machine-learning tools to bridge a detailed microscopic analysis with macroscopic
modelling of allosteric phenomena in cellular networks and signalling pathways.
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